Core Viewpoint - Geron Corporation is facing a class action lawsuit due to allegations of misleading statements regarding the growth potential of its drug Rytelo (imetelstat), leading to a significant drop in stock price after disappointing financial results were announced [1][2]. Summary by Sections Allegations - The complaint alleges that Geron provided investors with overly optimistic expectations about Rytelo's launch and growth potential, while downplaying risks related to monitoring requirements, seasonality, and competition [1]. - Following the announcement of fourth-quarter financial results for fiscal 2024, which revealed that Rytelo's growth had flattened, Geron's stock price fell from $2.37 to $1.61, a decline of approximately 32.07% in one day [1]. Class Action Details - The class period for the lawsuit is defined as February 28, 2024, to February 25, 2025, and shareholders are encouraged to register for participation [2]. - The deadline for shareholders to seek lead plaintiff status is May 12, 2025, and there is no cost to participate in the case [2]. Law Firm Information - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and illegal business practices [3]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [3].

Core Viewpoint - Geron Corporation is facing a class action lawsuit for alleged violations of the Securities Exchange Act of 1934, with claims that the company and its executives misled investors regarding the performance and market potential of its primary product, Rytelo [1][3]. Company Overview - Geron Corporation is a commercial-stage biopharmaceutical company focused on developing therapeutic products for oncology, with its main product being a telomerase inhibitor called imetelstat, marketed as Rytelo [2]. Allegations of the Lawsuit - The lawsuit alleges that Geron and its executives made false or misleading statements about the company's revenue outlook and growth potential, downplaying risks associated with seasonality and macroeconomic factors [3]. - It is claimed that the optimistic reports regarding Rytelo's launch success did not reflect the reality of market conditions, including competition and the need for ongoing monitoring of the treatment [3]. - The lawsuit further asserts that Rytelo lacked sufficient market awareness, hindering Geron's ability to meet the significant unmet need for the drug, particularly among first-line patients [3]. Financial Impact - Following the announcement of Geron's fourth-quarter financial results for fiscal year 2024 on February 26, 2025, which indicated a flattening growth for Rytelo, the company's stock price dropped by over 32% [4].

Core Viewpoint - Geron Corporation is facing a class action securities lawsuit due to alleged securities fraud related to the launch and growth potential of its drug Rytelo (imetelstat) [1][2] Group 1: Lawsuit Details - The lawsuit seeks to recover losses for Geron investors affected by alleged fraud between February 28, 2024, and February 25, 2025 [1] - Defendants allegedly provided misleading information regarding the expectations for Rytelo's market performance, downplaying risks associated with the drug's monitoring requirements and competition [2] - Following the announcement of flat growth for Rytelo and the factors contributing to it, Geron's stock price dropped from $2.37 to $1.61, a decline of approximately 32.07% in one day [2] Group 2: Next Steps for Investors - Investors who suffered losses during the relevant timeframe have until May 12, 2025, to request appointment as lead plaintiff [3] - Participation in the lawsuit does not require serving as a lead plaintiff, and there are no costs or obligations for class members [3] Group 3: Firm Background - Levi & Korsinsky has a history of securing significant settlements for shareholders and is recognized as a leading firm in securities litigation [4]

Core Viewpoint - Geron Corporation is facing a class action lawsuit due to allegations of misleading statements regarding the growth potential of its drug Rytelo (imetelstat), which led to a significant drop in stock price following disappointing financial results [3][4]. Summary by Relevant Sections Class Action Details - The class period for the lawsuit is from February 28, 2024, to February 25, 2025 [3]. - Shareholders are encouraged to contact the Gross Law Firm for possible lead plaintiff appointment, although it is not required to participate in any recovery [1][4]. Allegations Against Geron Corporation - The complaint alleges that Geron provided investors with overly optimistic expectations about Rytelo's launch and growth, while downplaying risks such as the monitoring requirement and competition [3]. - On February 26, 2025, Geron reported that Rytelo's growth had flattened, attributing this to seasonality, competition, lack of awareness, and monitoring burdens [3]. - Following this announcement, Geron's stock price plummeted from $2.37 to $1.61 per share, a decline of approximately 32.07% in one day [3]. Next Steps for Shareholders - The deadline for shareholders to register for the class action is May 12, 2025 [4]. - Registered shareholders will receive updates through a portfolio monitoring software throughout the case lifecycle [4]. Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud [5].

Core Viewpoint - Geron Corporation is facing a class action lawsuit due to allegations of misleading statements regarding the growth potential of its drug Rytelo (imetelstat), leading to a significant drop in stock price after disappointing financial results were announced [2][3]. Group 1: Allegations and Financial Impact - The class period for the lawsuit is from February 28, 2024, to February 25, 2025, during which Geron allegedly provided investors with overly optimistic expectations about Rytelo's market potential while downplaying associated risks [2]. - Following the announcement of fourth-quarter fiscal 2024 results on February 26, 2025, Geron reported that Rytelo's growth had flattened, attributing this to seasonality, competition, lack of awareness, and monitoring requirements, resulting in a stock price decline from $2.37 to $1.61, a drop of approximately 32.07% in one day [2]. Group 2: Next Steps for Shareholders - Shareholders who purchased GERN shares during the specified class period are encouraged to register for the class action by May 12, 2025, to potentially become lead plaintiffs and receive updates on the case [3]. - There is no cost or obligation for shareholders to participate in the case, and they will be enrolled in a portfolio monitoring system for status updates [3]. Group 3: Law Firm Background - The Gross Law Firm, which is handling the class action, is recognized for protecting investors' rights against deceit and fraud, aiming to hold companies accountable for misleading practices that inflate stock prices [4].

NEW YORK, April 30, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Geron Corporation (NASDAQ: GERN) between February 28, 2024 and February 25, 2025, both dates inclusive (the “Class Period”), of the important May 12, 2025 lead plaintiff deadline. SO WHAT: If you purchased Geron securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. W ...

NEW YORK, April 29, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Geron Corporation ("Geron" or the "Company") (NASDAQ: GERN) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Geron investors who were adversely affected by alleged securities fraud between February 28, 2024 and February 25, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/geron-corporation-lawsuit ...

Core Viewpoint - Geron Corporation is facing a class action securities lawsuit due to alleged securities fraud related to the launch and growth potential of its drug Rytelo (imetelstat) between February 28, 2024, and February 25, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that Geron misled investors regarding the expectations for Rytelo's market performance, downplaying risks associated with the drug's monitoring requirements and competition [2]. - Following the announcement of Geron's fourth-quarter financial results for fiscal 2024 on February 26, 2025, which revealed a flattening growth for Rytelo, the company's stock price dropped from $2.37 to $1.61 per share, a decline of approximately 32.07% in one day [2]. Group 2: Investor Information - Investors who suffered losses during the specified period have until May 12, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require serving in this role [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees, and there is no obligation to participate [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years and consistently ranking among the top securities litigation firms in the United States [4].

Core Viewpoint - Geron Corporation is facing a class action lawsuit due to alleged misleading statements regarding its revenue outlook and the market potential of its drug Rytelo, leading to significant stock price decline [3][4]. Group 1: Class Action Details - The class action lawsuit represents investors who purchased Geron securities between February 28, 2024, and February 25, 2025 [1]. - Investors are encouraged to contact the Portnoy Law Firm for a complimentary case evaluation and to discuss their legal rights [2]. Group 2: Allegations Against Geron - The lawsuit claims that Geron made false statements about its revenue outlook and growth potential, while downplaying risks related to seasonality and macroeconomic conditions [3]. - It is alleged that Geron's optimistic portrayal of Rytelo's launch was overstated, with significant impacts from seasonality, competition, and monitoring requirements [3]. - The lawsuit also states that Rytelo lacked sufficient market awareness to achieve meaningful penetration, particularly among first-line patients [3]. Group 3: Financial Impact - On February 26, 2025, Geron announced its fourth-quarter financial results for fiscal year 2024, revealing stagnation in Rytelo's growth attributed to seasonality, competitive pressures, and limited awareness [4]. - Following this announcement, Geron's stock price fell by more than 32% [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Geron Corporation securities between February 28, 2024, and February 25, 2025, of the May 12, 2025, deadline to serve as lead plaintiff in a class action lawsuit [1][2] Group 1: Class Action Details - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1] - A class action lawsuit has already been filed, and interested parties must move the Court by May 12, 2025, to serve as lead plaintiff [2] - The lawsuit alleges that Geron made false and misleading statements regarding the launch and profitability of its drug RYTELO, impacting investors' financial prospects [4] Group 2: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest settlement against a Chinese company at the time and being ranked No. 1 for securities class action settlements in 2017 [3] - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [3] - Founding partner Laurence Rosen was recognized as a Titan of Plaintiffs' Bar by Law360 in 2020, highlighting the firm's expertise and recognition in the field [3]